Evolus (NASDAQ:EOLS) Shares Gap Up – Time to Buy?

Evolus, Inc. (NASDAQ:EOLS)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $10.51, but opened at $12.98. Evolus shares last traded at $13.57, with a volume of 865,474 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th.

Evolus Price Performance

The company’s 50 day moving average price is $11.65 and its 200 day moving average price is $13.73. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm has a market capitalization of $888.08 million, a P/E ratio of -15.32 and a beta of 1.32.

Hedge Funds Weigh In On Evolus

Several hedge funds have recently added to or reduced their stakes in EOLS. Essex Investment Management Co. LLC lifted its holdings in shares of Evolus by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock valued at $4,788,000 after purchasing an additional 1,111 shares in the last quarter. Creative Planning boosted its position in Evolus by 23.7% during the 3rd quarter. Creative Planning now owns 15,451 shares of the company’s stock worth $250,000 after acquiring an additional 2,963 shares during the last quarter. Sei Investments Co. grew its position in Evolus by 9.8% in the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock valued at $367,000 after purchasing an additional 3,020 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Evolus by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock valued at $197,000 after buying an additional 4,780 shares during the last quarter. Finally, Quarry LP bought a new stake in Evolus during the 2nd quarter worth about $54,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.